A Phase 3 interventional study of Beclomethasone dipropionate and Beclomethasone dipropionate/Salbutamol combination in Bronchial Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 19 sites in 2 countries. Open to participants aged 1 Year to 4 Years. Per ClinicalTrials.gov, last updated 2020-08-03.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.
Among the 40 studies testing beclomethasone in Asthma, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is one of 20 in phase 3, and was the 11th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 1 Year to 4 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 22 · Phase 4 9
First in 1995; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 283 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 67 across the 40 interventional studies. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 40 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
81 studies in Asthma by Chiesi Farmaceutici S.p.A.: 11 open now, 11 under way, 2 of them phase 3. Of 69 finished, 13 (19%) have results posted.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 23rd largest by enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2006, is one of 24 in phase 3, and was the 7th registered.
Chiesi Farmaceutici S.p.A.’s Asthma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing beclomethasone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 81 in Asthma:
This tab as a report to print or save as PDF → With an account.
To demonstrate a superior efficacy of BDP plus rescue salbutamol suspension for nebulisation, compared to placebo plus rescue salbutamol, in the relief of symptoms of asthma in young children with persistent symptoms of asthma.
Asthma is a chronic disease which is estimated to affect over 25 million people both in the US and Europe(i.e. approximately 10% of the total population).There is evidence that over the last 20 years prevalence has considerably increased, especially among children. The diagnosis of asthma in children may be difficult, largely because episodic wheezing and cough are among the common symptoms encountered in childhood illnesses, particularly in children under 3 years old.Although in these young children there is the possibility of over treatment, the episodes of wheezing may be reduced in intensity by the effective use of anti-inflammatory medications and bronchodilators rather than antibiotics. At present, pharmacological therapy is used to treat reversible airway obstruction, inflammation and hyperreactivity in both children and adults. Medications include preventive treatments in forms of antinflammatory/antiallergic agents (e.g. glucocorticosteroids, leukotriene antagonists, cromolyn sodium) and reliever treatments, in form of bronchodilators (e.g. β-adrenergic agonists, anticholinergics). Comparisons: Beclomethasone suspension for nebulisation (400 mcg U.D.V.) plus as needed salbutamol compared to placebo plus as needed salbutamol and to as needed salbutamol/beclomethasone fixed combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients will be enrolled into the 2-week placebo run-in period if they meet all the following criteria:
Patients will be then randomised to the treatment period if they meet all the previous criteria plus:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Beclomethasone dipropionate
Drug: Beclomethasone dipropionate/Salbutamol combination
Drug: Salbutamol
Drug pages: Beclomethasone · Albuterol
Percentage of global (weeks 1-12) symptom-free days.
Time frame: weeks 1-12
Frequency and number of exacerbations (defined as a worsening of symptoms of asthma requiring extra oral or inhaled corticosteroids)
Time frame: weeks 1-12
Single clinical symptoms
Time frame: weeks 1-12 and every 2-week period
Nocturnal awakening due to symptoms of asthma
Time frame: weeks 1-12 and every 2-week period
Use of rescue nebulised therapy
Time frame: weeks 1-12 and every 2-week period
time to first exacerbation
Time frame: weeks 1-12
The record gives a start of Mar 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Beclomethasone · Albuterol